Third Arc Bio Inc: Valuation, Funding & Investors
Third Arc Bio Inc. is a clinical-stage biotechnology company developing novel multifunctional antibodies for a range of oncology and immunology & inflammation (I&I) indications. The company focuses on designing antibody therapeutics to address diverse tumor and immune-mediated disease mechanisms and is advancing a pipeline of clinical-stage candidates.
Leadership & Board
- Current Number of Employees
- 41
- Current LinkedIn Followers
- 3,928
Latest Estimated Valuation
- Total Amount Raised
- $52M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $52M
- Latest Funding Round
- Series A
Employee Trend
Third Arc Bio Inc had 41 employees as of November 16, 2026. The number of employees increased by 0 (0.00%) week-over-week.
Social Trend
Third Arc Bio Inc had 3,928 followers as of November 16, 2026. The number of followers increased by 4 (0.10%) week-over-week.
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Feb 04, 2026 | Series A | $52.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| Andreessen Horowitz | Series A |
| Marshall Wace | Series A |
| Omega Funds | Series A |
| BVF Partners LP | Series A |
| Life Sciences at Goldman Sachs Alternatives | Series A |
| accounts advised by T. Rowe Price Associates, Inc. | Series A |
| AbbVie Ventures | Series A |
| Alderline Group | Series A |
Similar Companies
A snapshot of private companies similar to Third Arc Bio Inc, helping you discover and navigate related company profiles.
Related News and Analysis








